Azenta, Inc. (NASDAQ:AZTA – Get Free Report) has earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $40.40.
A number of equities analysts recently commented on the company. Needham & Company LLC cut their price objective on Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th.
Check Out Our Latest Stock Report on AZTA
Institutional Investors Weigh In On Azenta
Azenta Price Performance
Shares of NASDAQ:AZTA opened at $28.28 on Thursday. The firm has a 50 day simple moving average of $24.34 and a 200 day simple moving average of $25.86. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -7.14 and a beta of 1.37. Azenta has a one year low of $15.93 and a one year high of $41.73.
Azenta (NASDAQ:AZTA – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The firm had revenue of $144.79 million during the quarter, compared to analyst estimates of $148.47 million. During the same period in the previous year, the company earned $0.01 EPS. Azenta’s revenue for the quarter was up 1.4% on a year-over-year basis.
Azenta Company Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
See Also
- Five stocks we like better than Azenta
- Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race
- Survey Reveals: 62% of US Households Are Cutting Back on Protein as Grocery Prices Rise [2026]
- UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
